Linked Life Data

11702959

Source:http://linkedlifedata.com/resource/pubmed/id/11702959

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2001-11-12
pubmed:abstractText
Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-Hodgkin's lymphoma (NHL). Of the 653 patient records reviewed, 90 (14%) omitted an anthracycline or mitoxantrone (Novantrone) from primary therapy. Among patients receiving CHOP (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone) or CNOP (cyclophosphamide, mitoxantrone, vincristine, prednisone), 134 (27%) of 492 received an average relative dose intensity of less than 80% of the literature-referenced dose, due either to an inadequate planned or delivered dose. Of 181 advanced-stage patients with responsive disease, 28 (15%) failed to receive at least six treatment cycles. Overall, 283 (43%) of 653 patients potentially received suboptimal chemotherapy due either to choice of regimen or chemotherapy delivered. Patient age > or = 65 years and cardiac comorbidity appeared to have the greatest influence on a physician's decision regarding chemotherapy administration. Among the 492 patients who received CHOP or CNOP, 235 (48%) experienced a delay or reduction in chemotherapy dose (usually neutropenia-related), 100 (20%) developed mucositis, and 116 (24%) were hospitalized for febrile neutropenia. Growth factor was administered to 261 patients (53%), and its primary prophylactic use was associated with a significant reduction in the incidence of hospitalizations for febrile neutropenia in all patient subgroups receiving appropriate chemotherapeutic dose intensity (P = .02). This assessment of chemotherapy delivery to patients with intermediate-grade NHL showed significant variation from current standards. Further analysis of factors influencing chemotherapy delivery might improve therapeutic outcomes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0890-9091
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1296-306; discussion 1310-1, 1314
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:11702959-Adolescent, pubmed-meshheading:11702959-Adult, pubmed-meshheading:11702959-Aged, pubmed-meshheading:11702959-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11702959-Cyclophosphamide, pubmed-meshheading:11702959-Disease-Free Survival, pubmed-meshheading:11702959-Dose-Response Relationship, Drug, pubmed-meshheading:11702959-Doxorubicin, pubmed-meshheading:11702959-Female, pubmed-meshheading:11702959-Growth Substances, pubmed-meshheading:11702959-Humans, pubmed-meshheading:11702959-L-Lactate Dehydrogenase, pubmed-meshheading:11702959-Lymphoma, Non-Hodgkin, pubmed-meshheading:11702959-Male, pubmed-meshheading:11702959-Middle Aged, pubmed-meshheading:11702959-Mitoxantrone, pubmed-meshheading:11702959-Neutropenia, pubmed-meshheading:11702959-Prednisolone, pubmed-meshheading:11702959-Prednisone, pubmed-meshheading:11702959-Reference Values, pubmed-meshheading:11702959-Retrospective Studies, pubmed-meshheading:11702959-Severity of Illness Index, pubmed-meshheading:11702959-Time Factors, pubmed-meshheading:11702959-Vincristine
pubmed:year
2001
pubmed:articleTitle
Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
pubmed:affiliation
Section of Hematology/Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA. hemvjp@vmmc.org
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't